





































































To describe  the state of  the public and private malaria diagnostics market shortly after  the World 








3,439  RDT  products  from  39  manufacturers  were  audited  among  12,197  outlets  interviewed. 
Availability was typically highest in public health facilities, though availability in these facilities varied 
greatly across countries, from 15% in Nigeria to over 90% in Madagascar and Cambodia. Private for‐
profit sector availability was 46%  in Cambodia, 20%  in Zambia, but  low  in other countries. Median 






source  of  fever  treatment,  the  goal  of  universal  diagnosis  will  not  be  achievable  under  current 















To  reach  the  target  of  universal  diagnosis,  there  is  growing  attention  in  finding  scalable  and 
sustainable models of RDT  access  and demand  in  the private  sector  (UNITAID 2012; MalariaCare 
2013). The WHO estimates that, worldwide, 40% of children with fever seek treatment from some 
form  of  private  provider,  including  formal  health  facilities,  pharmacies,  drug  shops  and  informal 
medicine vendors (WHO 2011a).  










be considered representative  (Albertini et al. 2012a). One partial exception  is  in Cambodia, where 

















(AMFm),  which  drew  on  ACTwatch  methods  (Ghana,  Kenya  and  Tanzania;  data  from  Tanzania‐
mainland  and  Zanzibar  are  presented  separately).  Survey methods  have  been  described  in  detail 
previously  (O’Connell et al. 2011; Shewchuk et al. 2011; Tougher et al. 2012; AMFm  Independent 
Evaluation Team 2012). Briefly, nationally representative cluster surveys of outlets with the potential 





conducted  in  Zanzibar  given  its  small population  size. Within  each  cluster  a  full  census of health 
facilities, community health workers (CHWs) and retail outlets with the potential to stock antimalarials 
was  conducted. Given  their  relatively  low  numbers,  public  health  facilities  and  pharmacies were 
oversampled, most commonly by drawing additional outlets from a larger geographical area. 
Eligibility criteria for the studies were any outlet with antimalarials in stock on the day of the survey 
or  reporting  having  stocked  antimalarials  during  the  previous  three months.  Providers  in  eligible 









using  survey weights, and 95% confidence  intervals  for availability were  calculated accounting  for 



















report  and  was  not  assessed  by  the  interviewer.  Availability  of  any  RDT  was  calculated  as  the 
proportion of outlets with at least one RDT audited. There is interest in assessing availability of RDTs 
meeting  specified quality  standards. However, quality  results  are  specific  to  the parasite  species, 
antigen(s), and  type of  test  (cassette, card, dipstick, etc)  (WHO 2011b). As  these details were not 
collected during  the outlet  survey,  a  proxy measure was  used  of whether  the manufacturer had 
submitted any RDT to Rounds 1‐3 (2008‐2011) of WHO/FIND RDT product testing (WHO 2011b), as an 
indicator that the manufacturer had a demonstrable interest in product quality. Manufacturer names 
recorded on  the RDT audit  sheets were  compared against  those who  submitted at  least one RDT 






prices did not  include  consultation or  registration  fees which may be  charged by  certain  types of 










from  less  than one‐in‐five  in Nigeria  (15%) and Kenya  (19%)  to over 90%  in Cambodia  (94%) and 
Madagascar  (92%). RDTs were  stocked by CHWs  in  three  countries: Cambodia  (97%), Madagascar 
(54%) and Uganda (70%). Relatively few private not‐for‐profit health facilities were interviewed in the 
























RDTs  from 39 manufacturers were recorded  in  the 10 surveys, with  the number of manufacturers 
found  in each survey ranging from 2  in Tanzania‐mainland to 23  in Uganda (Table 2). Across study 
countries  SD  Bioline  products  from  Standard  Diagnostics  and  Paracheck  products  from  Orchid 
Biomedical  Systems  were  most  commonly  present,  each  being  audited  in  8  countries.  CareStart 
products  from Access Bio,  Inc were audited  in 7 countries. Diversity  in brand availability between 
public/not‐for‐profit  and  private‐for‐profit  sectors  was  greatest  in  Uganda,  where  nine  unique 




All  RDTs  indentified  in  Cambodia,  Ghana,  Tanzania‐mainland,  Zambia  and  Zanzibar  were  from 
manufacturers  participating  in  WHO/FIND  product  testing.  In  countries  where  RDTs  from  non‐
submitting manufacturers were present, availability of non‐submitted product across outlet  types 


























highest  for  products  audited  in  public  health  facilities, where  it  ranged  from  three  in  Benin  and 







The  availability  of  diagnostic  testing  documented  in  the  public  and  private  sectors  in  this  study 
indicates  clearly  that  the goal of universal parasitological diagnosis  (WHO 2010)  is  far  from being 
achieved. Although availability of any diagnostic test was higher in public health facilities than in the 
private sector, it was less than 60% in public health facilities in five countries. However, in Cambodia, 





RDT availability  in the private sector was 10% or  less  in seven of the ten surveys. For the nine sub‐
Saharan African settings, private sector RDT availability was typically less than 15% for all private for‐











and  in 2010 PSI distributed over 800,000  test kits nationwide  (PSI 2011). The  results  in Cambodia 
suggest  that  such  an RDT  intervention may be one  approach  to  increase  access  at  scale,  though 
improvements in RDT availability and uptake were relatively slow, particularly in more remote areas 
(Yeung et al. 2011). 
Substantial  increases  in  availability of  effective  antimalarials have  resulted  from other  large‐scale 
private sector interventions, though these have not targeted RDT availability. Results from the AMFm 
show national‐level ACT  subsidies  can  lead  to  large  increases  in ACT  availability  in private health 
facilities and retail outlets, in some settings (Tougher et al. 2012). The AMFm pilot intervention was 
hosted by the Global Fund and comprised negotiated manufacturer price reductions, a co‐payment to 




The  results  presented  here  imply  that  presumptive  treatment  of  febrile  illness  is  currently  very 
common.  Several  potential  consequences  of  this  include:  inefficient  resource  allocation  by 
governments and donors, unnecessary out‐of‐pockets expenses for households, increased risk of drug 
resistance  through  overtreatment  with  ACTs  (Perkins  et  al.  2008),  and  increased  morbidity  and 
mortality when the true source of illness is left untreated. The question of what role the private sector 
should play with  regards  to diagnosis  is  characterized by  a  lack of empirical evidence  and  strong 

















is  the  existing  regulatory  framework, which  frequently prohibits  retail providers  from performing 
consultations and offering an RDT service or selling RDTs. Consistent with this, the  lack of existing 
referral  systems  from private  retail outlets  to public  facilities poses an  important  challenge when 
addressing an intervention that is a health service as opposed to the provision of a commodity. These 









program  in Kenya  increased  the proportion of  illness episodes  that were  tested  for malaria by 22 
percentage  points  across  all  subsidy  levels  (Cohen  et  al.  2012b).  A  systematic  review  of  rapid 
diagnostic test performance by CHWs reported a high overall quality of care was achieved, though 































Second,  the operational definitions of  two  indicators are  limited by  the available data.  In order  to 
define RDT quality, either recorded brand characteristics such as parasite species must be compared 
against lists such as the WHO selection criteria for RDT procurement (WHO 2012b) or the Global Fund 
Quality Assurance Policy  (Global Fund 2014), or RDT  samples must be purchased  in  the  field and 
tested. The latter was considered beyond the scope of this study. In addition, the data collected did 
not include details of parasite species or lot numbers for RDT products. We thus defined quality on 
the basis of manufacturer  submission  for WHO/FIND  testing,  rather  than on product‐specific  test 
results. Study results do not therefore directly provide information on quality‐assured RDTs as defined 
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Table 1. Sample description – total number of outlets visited and screened, number of eligible1 outlets interviewed, and number of RDT products audited 
 
Public / private not-for-profit sector 
(public health facilities, community health workers 
and private not-for-profit health facilities) 
Private for-profit sector 
(private for-profit health facilities, pharmacies 


























Benin 351 330 315 308 79 376 352 341 328 17 
Cambodia 818 873 739 739 701 1,440 1,356 580 569 295 
Ghana 341 321 316 316 99 740 670 652 646 17 
Kenya 854 837 477 477 74 1,225 1,074 1,046 1,033 70 
Madagascar 1,607 1,482 773 771 698 632 554 517 509 24 
Nigeria 161 134 122 122 22 1,574 1,338 1,326 1,322 22 
Tanzania-mainland 71 68 65 65 24 772 713 710 710 16 
Uganda 1,787 1,756 832 830 481 2,662 2,476 2,429 2,373 362 
Zambia 307 297 296 296 198 495 448 425 416 80 
Zanzibar 169 164 147 147 140 315 271 220 220 20 
Total 6,466 6,262 4,082 4,071 2,516 10,231 9,252 8,246 8,126 923 
RDT: rapid diagnostic test. 
1 An eligible outlet either had antimalarials in stock on the day of interview or had stocked antimalarials in the past three months. Not all visited outlets were 
screened; reasons include outlets that had closed down permanently, outlets that were closed on each visit, and outlets with no eligible respondents available at 
the time of interviews. 
 
  
All tables and figures
Figure 1. Availability of any RDT in outlets that have stocked antimalarials in the past 3 months, including the day of interview, among (a) public/not-for-profit sector outlets, and (b) private for-profit sector 
 outlets (2011) 
 (a) Public/not-for-profit sector outlets 




























































































Private for-profit health facility Registered pharmacy Drug shop
Error bars show 95% confidence interval bounds.  
A full census of outlets was conducted in Zanzibar. 















































Access Bio Inc CareStart Yes X  X X X X X X X X X     X     
Acon Biotech Unspecified /  Plasmostesta Yes  X  X  X     X X    X     
Acumen Diagnostics Diaspot No           X X         
Aragen Biotech Unspecified No                X     
Astel Diagnostics Astel Pf Cassette No               X X     
Atlas Link Technology Nova Test No               X X     
Atlas Medical Rapid Test Strip No X                    
Bhat Biotech India MaleriScan Yes  X              X     
Bioland NanoSign Yes        X          X   
Biosynex Unspecified Yes                X     
Bio Vege Med Unspecified No X                    
Blue Cross Bio-Medical Malaria Pf Yes      X               
Chian Pharmed Co Unspecified No  X                   
CTK Biotech On Site Rapid Test Yes                X  X   
Cypress Diagnostics Malaria Quick Test No          X     X X     
Diagnostics Automation Unspecified Yes                    X 
Euromedi Eurocheck No        X             
Global Device Unspecified No           X X         
Highgate Whole Blood Cassette No                X     
Human GMBH Hexagon Malaria Yes                X     
ICT Diagnostics ICT Yes X X     X X      X   X X  X 
InTec Products Advanced Quality Yes    X                 
Inverness Medical Binax Now Malaria Yes   X                  
Jei Daniel Biotech Unspecified No X                    
Lab-care Diagnostics Accucare One Step No               X X     
Launch Diagnostics Accusay No               X      
Medsource Ozone Biomedicals Malaria Antibody Test No X                    
Nano Biotech Nano Malaria No                X     
Nantong Egnes Biotech Unspecified No                X     
Omega Diagnostics Micropath No            X         
Orchid Biomedical Systems Paracheck Yes X X X    X X X  X X    X X  X X 
Pistis Diagnostic Ltd Unspecified No           X          
Premier Medical Corporation First Response Yes     X X X X   X X   X X  X   
Span Diagnostics Parahit Yes                X     
SSA Diagnostics and Biotech Systems Unspecified Yes                X     
Standard Diagnostics SD Bioline Yes X X     X X X X X X X X X X X X X X 
Vision Biotech Clear Viewb Yes          X     X X    X 
Wondfo Biotech One Step Whole Blood Testc Yes   X X  X X X    X   X X     
Zephyr Biomedicals Unspecified Yes       X             X 
Unspecified Life Tech Whole Blood Strip n/a               X      
RDT: rapid diagnostic test; NFP: not-for-profit 
a Brand details were recorded as Plasmotest in Benin, but not recorded for RDTs from Acon Biotech in other countries; b Brand details were not recorded for 2 Vision Biotech RDTs audited in Madagascar and 1 RDT audited in Zanzibar;  
c Brand details were not recorded for 2 Wondfo Biotech RDTs audited in Ghana; in Cambodia 25 RDTs from Wondfo Biotech were branded as Malacheck, the brand name used by PSI’s subsidised RDT program. 
  
































































































































































































RDT: rapid diagnostic test; IQR: Interquartile range 
The unit of analysis is RDT products; generally an outlet or facility would only have one product type (brand) in stock on the day of interview. 
A full census of outlets was conducted in Zanzibar. 
1 In Ghana, Kenya, Madagascar, Nigeria, Tanzania, Uganda and Zanzibar, the median price is the price charged to purchase an RDT for a child; in the other countries no age group 
was specified in the question to respondents. 
2 Prices converted to US dollars using the average country exchange rate for 2011, but not adjusted to reflect local purchasing power in each country. 
  

































































































































































































RDT: rapid diagnostic test; CHW: Community health worker; IQR: Interquartile range 
A full census of outlets was conducted in Zanzibar. 
1 Providers were asked to report how many tests had been sold or used during the past 7 days for each RDT product in stock on the day of interview. In some cases the providers 
refused or could not recall the number of tests. These data have been set to missing for this analysis and account for the following proportion of total RDT cases in each country: 
Benin (15%), Ghana (6%), Kenya (6%), Madagascar (5%), Nigeria (5%), Tanzania-mainland (10%), Uganda (4%), Zambia (6%), Zanzibar (4%). 
  




















Percent (95% CI) Percent (95% CI) Percent (95% CI) Percent (95% CI) Percent (95% CI) Percent (95% CI) Percent (95% CI) Percent (95% CI) 
Benin 




21.8 (5.4, 57.5) 
N=64 
11.2 (7.3, 16.8) 
N=301 
12.3 (2.9, 39.2) 
N=133 




10.6 (2.7, 33.7) 
N=324 
Cambodia 
93.9 (90.1, 96.3) 
N=394 




95.7 (93.2, 97.3) 
N=739 
65.7 (54.3, 75.5) 
N=133 
27.9 (15.5, 45.0) 
N=77 
43.8 (34.4, 53.7) 
N=359 
46.1 (38.5, 54.0) 
N=569 
Ghana 




7.9 (1.6, 31.0) 
N=13 
27.5 (19.7, 37.0) 
N=316 
12.4 (4.8, 28.6) 
N=23 
4.0 (2.6, 6.1) 
N=275 
0.2 (<0.1, 1.3) 
N=348 
1.4 (0.9, 2.4) 
N=646 
Kenya 




8.6 (3.5, 19.7) 
N=42 
16.6 (9.1, 38.4) 
N=475 
8.2 (4.9, 13.3) 
N=278 
6.7 (3.8, 11.8) 
N=255 
3.1 (1.5, 6.6) 
N=490 
5.2 (3.6, 7.3) 
N=1,023 
Madagascar 
91.8 (88.6, 94.2) 
N=637 
54.1 (39.9, 67.6) 
N=101 
71.5 (40.4, 90.3) 
N=29 
70.3 (69.1, 79.5) 
N=767 
8.5 (3.8, 17.8) 
N=49 
6.5 (3.2, 12.7) 
N=73 
1.5 (0.6, 3.4) 
N=387 
3.7 (2.2, 6.3) 
N=509 
Nigeria 




16.9 (2.4, 62.3) 
N=9 
14.2 (7.0, 26.5) 
N=117 
8.5 (3.3, 19.9) 
N=92 
6.0 (0.8, 33.8) 
N=35 
0.8 (0.3, 2.4) 
N=1,172 








25.2 (3.4, 76.2) 
N=5 
37.8 (22.7, 55.6) 
N=63 
3.4 (0.6, 17.8) 
N=25 
4.9 (2.2, 10.6) 
N=304 
0.9 (0.2, 3.6) 
N=369 
1.2 (0.4, 3.3) 
N=698 
Uganda 
53.0 (44.7, 61.2) 
N=674 
70.2 (36.4, 90.6) 
N=107 
51.3 (30.7, 71.5) 
N=38 
61.5 (42.0, 77.9) 
N=819 
20.8 (16.0, 26.5) 
N=811 
30.1 (21.7, 40.1) 
N=389 
4.6 (3.1, 6.7) 
N=1,153 
9.6 (7.1, 12.9) 
N=2,353 
Zambia 




46.2 (12.1, 84.2) 
N=9 
69.1 (55.9, 79.7) 
N=291 
43.8 (23.6, 66.2) 
N=50 
41.1 (29.1, 54.2) 
N=96 
9.7 (2.0, 36.8) 
N=267 



















RDT: rapid diagnostic test; CI: confidence interval 



















































Public health facility Total public / not-for-profit sector Total private for-profit sector
Error bars show 95% confidence interval bounds.  
A full census of outlets was conducted in Zanzibar. 
Supplementary Table 2. Availability of any RDT from a manufacturer that has submitted product(s) for testing during WHO/FIND Rounds 1-3 in outlets that stocked antimalarials 




















Percent (95% CI) Percent (95% CI) Percent (95% CI) Percent (95% CI) Percent (95% CI) Percent (95% CI) Percent (95% CI) Percent (95% CI) 
Benin 




18.2 (3.1, 60.8)  
N=63 
10.6 (7.0, 15.6)  
N=298 
10.6 (2.1, 40.3)  
N=131 




9.2 (1.9, 34.4)  
N=322 
Cambodia 
93.9 (90.1, 96.3)  
N=393 




95.7 (93.2, 97.3)  
N=738 
63.1 (52.0, 72.9)  
N=131 
27.9 (15.5, 45.0)  
N=77 
41.8 (32.1, 52.1)  
N=346 
44.0 (36.3, 52.0)  
N=554 
Ghana 






26.4 (18.7, 35.9)  
N=315 
12.4 (4.8, 28.6)  
N=23 
3.7 (2.3, 5.9)  
N=274 
0.2 (0.0, 1.3)  
N=348 
1.4 (0.8, 2.4)  
N=645 
Kenya 




5.0 (1.3, 17.5)  
N=41 
15.5 (8.0, 27.7)  
N=470 
7.3 (4.0, 12.8)  
N=271 
5.5 (3.2, 9.5)  
N=250 
2.7 (1.3, 5.5)  
N=489 
4.5 (3.0, 6.7)  
N=1,010 
Madagascar 
91.7 (88.4, 94.1)  
N=636 
54.1 (39.9, 67.6)  
N=101 
71.5 (40.4, 90.3)  
N=29 
70.2 (59.0, 79.4)  
N=766 
7.4 (3.3, 15.8)  
N=49 
6.5 (3.2, 12.7)  
N=73 
1.5 (0.6, 3.4)  
N=387 
3.5 (2.0, 5.9)  
N=509 
Nigeria 




16.5 (2.3, 62.5)  
N=9 
7.9 (3.7, 16.0)  
N=117 




0.8 (0.3, 2.4)  
N=1,172 








25.2 (3.4, 76.2)  
N=5 
35.9 (20.5, 55.0)  
N=60 
3.4 (0.6, 17.8)  
N=25 
2.9 (0.8, 10.3)  
N=300 
0.9 (0.2, 3.6)  
N=369 
1.1 (0.4, 3.3)  
N=694 
Uganda 
51.3 (43.4, 59.2)  
N=673 
70.2 (36.4, 90.6)  
N=107 
36.5 (18.2, 59.8)  
N=38 
59.3 (39.1, 76.8)  
N=818 
15.1 (11.2, 20.1)  
N=802 
11.1 (6.8, 17.6)  
N=387 
3.7 (2.3, 5.9)  
N=1,152 
7.0 (5.1, 9.6)  
N=2,341 
Zambia 




46.2 (12.1, 84.2)  
N=9 
69.1 (55.9, 79.9)  
N=291 
43.8 (23.6, 66.2)  
N=50 
40.2 (27.8, 54.0)  
N=96 
7.5 (1.6, 28.4)  
N=266 



















RDT: rapid diagnostic test; CI: confidence interval 
A full census of outlets was conducted in Zanzibar. 
 
  
Supplementary Table 3. Availability of any RDT from a manufacturer that has not submitted product(s) for testing during WHO/FIND Rounds 1-3 in outlets that stocked 


























2.6 (0.7, 8.9)  
N=63 
0.2 (0.0, 1.6)  
N=298 















































1.4 (0.2, 8.9)  
N=41 




0.4 (0.1, 1.6)  
N=250 
0.4 (0.1, 2.3)  
N=489 

















0.2 (0.1, 0.7)  
N=509 
Nigeria 




0.4 (0.0, 3.5)  
N=9 
6.2 (2.3, 16.1)  
N=117 
1.5 (0.3, 7.7)  
N=92 
6.0 (0.8, 33.8)  
N=35 
<0.1 (0.0, 0.1)  
N=1,172 

























14.8 (3.7, 44.2)  
N=38 
1.6 (0.4, 6.4)  
N=818 
5.4 (3.5, 8.3)  
N=802 
19.3 (12.4, 28.7)  
N=387 
0.7 (0.3, 1.5)  
N=1,152 




































RDT: rapid diagnostic test; CI: confidence interval 
A full census of outlets was conducted in Zanzibar. 
 
